Camizestrant Recommended for 1st-Line ER-Positive Breast Cancer in EU
Camizestrant, in combination with CDK4/6 inhibitor, has been recommended for approval in the EU for 1st-line advanced ER-positive breast cancer based on SERENA-6 trial results.
Indication
Clinical and regulatory intelligence for ER-positive Breast Cancer with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.